Patient-reported outcomes in Philadelphia chromosome-positive acute lymphoblastic leukemia patients treated with ponatinib or imatinib: results from the PhALLCON trial.

Here we report patient-reported outcomes (PRO) from PhALLCON assessed as exploratory endpoints using the Functional Assessment of Cancer Therapy-Leukemia (FACT-Leu) and EQ-5D-5L.

在这里，我们报告了使用癌症治疗功能评估-白血病（FACT-Leu）和EQ-5D-5L评估的PhALLCON试验中的患者报告结果（PRO），作为探索性终点。

Primary PRO domains included FACT-G physical well-being, FACT-Leu subscale (FACT-LeuS), Trial Outcome Index (TOI), FACT-Leu total score, FACT-G total score, and EQ-5D visual analogue scale.

主要的患者报告结果（PRO）领域包括功能性评估癌症治疗-一般（FACT-G）身体福祉、白血病特定子量表（FACT-LeuS）、试验结果指数（TOI）、FACT-Leu总分、FACT-G总分以及欧洲五维健康量表（EQ-5D）视觉模拟量表。

Differences in least-squares mean score changes from baseline to the end of induction (EOI)/consolidation (EOC) and time to confirmed improvement/deterioration were analyzed.

分析了从基线到诱导治疗结束（EOI）/巩固治疗结束（EOC）的最小二乘平均分数变化差异，以及确认改善或恶化的时长。

Overall treatment tolerability was assessed using the FACT-GP5.

使用FACT-GP5评估了整体治疗的耐受性。

Analyses included 238 patients (ponatinib 159, imatinib 79) with ≥1 PRO assessment.

分析包括了238名患者（ponatinib 159名，imatinib 79名），这些患者至少进行了1次患者报告结果（PRO）评估。

Least-squares mean changes from baseline favored ponatinib, with significant and meaningful differences in FACT-LeuS, TOI, and FACT-Leu total score at EOI and across the primary domains except for FACT-LeuS at EOC.

从基线开始的最小二乘平均变化更倾向于Ponatinib，在终点评估时，FACT-LeuS、TOI和FACT-Leu总分显示出显著且有意义的差异，并且在主要领域中也是如此，除了终点评估时的FACT-LeuS。

Median time to confirmed improvement was shorter with ponatinib versus imatinib for key measures.

与伊马替尼相比，Ponatinib的关键指标确认改善的中位时间更短。

Ponatinib-treated patients tended to report being less bothered by treatment side effects as assessed by FACT-GP5.

根据FACT-GP5评估，接受Ponatinib治疗的患者倾向于报告较少受到治疗副作用的困扰。

These findings highlight ponatinib's potentially favorable impact on health-related quality of life, supporting its use as frontline treatment for Ph+ ALL.

这些发现突显了Ponatinib对健康相关生活质量可能产生的有利影响，支持将其作为Ph+ ALL的一线治疗药物。